RMC-0708

News alerts, weekly reports and conference planners

Company:

Revolution Medicines

Drug class:

KRAS Q61H inhibitor

‹

›

KRAS Q61H	Pancreatic Ductal Adenocarcinoma	KRAS Q61H	Pancreatic Ductal Adenocarcinoma	RMC-0708 Sensitive: D – Preclinical RMC-0708 Sensitive : D	RMC-0708 Sensitive: D – Preclinical RMC-0708 Sensitive : D
KRAS Q61H	Non Small Cell Lung Cancer	KRAS Q61H	Non Small Cell Lung Cancer	RMC-0708 Sensitive: D – Preclinical RMC-0708 Sensitive : D	RMC-0708 Sensitive: D – Preclinical RMC-0708 Sensitive : D

Associations
(2)